SCHEMBL670243

SCHEMBL670243

CCCCCC(C(=O)O)S(=O)(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.50
FFAR1 O14842 1/20 0.50
MAPT P10636 1/20 0.48
TP53 P04637 1/20 0.48
LCK P06239 1/20 0.48
PPARD Q03181 1/20 0.48
ZDHHC20 Q5W0Z9 1/20 0.48
ZDHHC2 Q9UIJ5 1/20 0.48
ACE2 Q9BYF1 1/20 0.46
GRIK1 P39086 2/20 0.43
GRIK2 Q13002 2/20 0.43
SLC1A2 P43004 1/20 0.43
SLC1A1 P43005 1/20 0.43
CHRM1 P11229 1/20 0.43
AKR1A1 P14550 1/20 0.43
CHRM3 P20309 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
ADRA1A P35348 1/20 0.43
HRH1 P35367 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8572246 0.98 GPR84 (0.53) GPR84FFAR1MAPTTP53LCK
SCHEMBL29411296 0.98 GPR84 (0.53) GPR84FFAR1MAPTTP53LCK
SCHEMBL1158129 0.98 GPR84 (0.53) GPR84FFAR1MAPTTP53LCK
SCHEMBL1157909 0.98 GPR84 (0.53) GPR84FFAR1MAPTTP53LCK
SCHEMBL3495263 0.98 GPR84 (0.53) GPR84FFAR1MAPTTP53LCK
SCHEMBL7609463 0.98 GPR84 (0.53) GPR84FFAR1MAPTTP53LCK
SCHEMBL9437254 0.98 GPR84 (0.53) GPR84FFAR1MAPTTP53LCK
SCHEMBL3495447 0.98 GPR84 (0.53) GPR84FFAR1MAPTTP53LCK
SCHEMBL8574512 0.98 GPR84 (0.53) GPR84FFAR1MAPTTP53LCK
SCHEMBL28201959 0.98 GPR84 (0.53) GPR84FFAR1MAPTTP53LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119278054-A Glycosylated prodrugs 莱顿大学 2025-01-07 CN disclosed
CN-119012999-A Improved nasal administration of pharmaceutical formulations 思瑞诺医疗有限公司 2024-11-22 CN disclosed
CN-115844903-A Application of betulin derivative in preparation of bacteria inhibiting medicine 潍坊赛宝工业技术研究院有限公司 2023-03-28 CN disclosed
CN-114206396-A Methods and compositions for attenuating an immune response against an antiviral transfer vector 西莱克塔生物科技公司 2022-03-18 CN disclosed
EP-2349999-B1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIV SAARLAND (DE) 2016-01-27 EP disclosed
US-8912186-B2 Allosteric protein kinase modulators UNIVERSITAET DES SAARLANDES (DE) 2014-12-16 US disclosed
US-20120046307-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046307-A1 ALLOSTERIC PROTEIN KINASE MODULATORS AURKC, AURKA, AURKB GPR84 3246/4885FFAR1 4188/4885MAPT 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.